Eternum to Exhibit at Clinic Management Forum in Fukuoka, Showcasing Next-Generation Regenerative Beauty Products

Eternum Inc. of Shibuya, Tokyo, led by Representative Director Takaaki Matsumoto, will exhibit at Clinic Management Forum in Fukuoka, to be held on Sunday, May 17, 2026, at Daimyo Conference. The company’s mission is to “create a future where the dream of eternal beauty does not end as just a dream.” At the event, Eternum will propose the potential of next-generation treatments and products that apply insights from regenerative medicine, under the theme of sustainable growth and higher added value in aesthetic medicine. The company will display and sell a range of products, including the medical institution-exclusive Eternum DR series and a topical lip serum highly formulated with human umbilical cord-derived mesenchymal stem cell culture supernatant. At the booth, Eternum will also introduce its formulation design focused on cellular activity, support programs for clinics adopting the products, and education, sales promotion, and marketing support. Visitor benefits include 20% off all products, an Eternum DR mini trial set for completing a questionnaire, 10 Eternum DR mini trial sets for confirming a business meeting appointment on site, and a sample of the visitor’s choice for following the official Instagram account or adding the brand on LINE. Individually sold facial mask sheets are excluded from the discount. The mini trial set includes skincare and lip serum samples. Eternum DR is a skincare series exclusively sold through medical institutions and developed from research in regenerative medicine. It uses advanced umbilical cord-derived stem cells and a formulation incorporating exosomes and cytokines to help achieve “timeless skin,” defined as skin with firmness and radiance through moisture. Eternum is recruiting medical institutions of all types to carry Eternum DR and welcomes clinics seeking to offer next-generation regenerative beauty. Special consultation sessions for product introduction will be available during the event. The event will be held from 10:00 to 17:20 on Sunday, May 17, 2026, at Daimyo Conference, 2-6-50 Daimyo, Chuo-ku, Fukuoka City, Fukuoka 810-0041. It is intended for clinic owners, physicians, administrative directors, and other clinic-related professionals. As a rule, participation by non-clinic-related attendees is not accepted. Admission is free, and attendees may enter and leave during the event. Eternum says it conducts a series of safety tests so customers can use its products every day with confidence. For donors, umbilical cords are collected from healthy donors at Japanese medical institutions after appropriate consent is obtained, and all HBV, HCV, HIV, HTLV, PVB19, and TP tests are confirmed negative. Mesenchymal stem cells obtained from umbilical cords are tested for sterility, mycoplasma, viruses, endotoxins, and karyotype analysis, with results confirmed negative or not detected. The manufactured culture supernatant is also tested for sterility, endotoxins, mycoplasma, and insoluble foreign matter, with all results confirmed negative or not detected. For new cosmetic ingredients, Eternum conducts and clears nine tests at a level comparable to quasi-drug standards: single-dose toxicity, skin sensitization, photosensitization, reverse mutation, chromosomal aberration, primary skin irritation, eye irritation, repeated skin irritation, and phototoxicity tests. The company also conducts eight product safety tests: patch testing, sensitive skin patch testing, stinging testing, RIPT allergy testing, non-comedogenic testing, challenge testing, three-month continuous-use efficacy testing, and anti-wrinkle testing. While safety testing for new ingredient development is often based on voluntary standards and may involve only a few tests such as patch testing, Eternum says it conducts a total of 17 tests across two stages, including sensitive skin patch tests for allergy and alcohol-related concerns. Eternum’s product lineup includes medical institution-exclusive Eternum DR skincare, Eternum DR Lip Serum, and Eternum DR Skin Glow Mask EX, as well as Eternum skincare lotions, serums, creams, trial sets, cleansing oil, face wash, Essence UV Primer, lip serums, eyelash serum, SAITAI culture supernatant concentrate, and Facial Mask EX. Eternum is a skincare brand born from regenerative medicine research. It offers lip serums, medical institution-exclusive skincare, and consumer skincare. “Eternum” means “eternal” in Latin, and the brand aims to deliver unprecedented beauty through a proprietary culture supernatant derived from rare, high-value umbilical cord-derived mesenchymal stem cells. Eternum says it seeks to be a brand that accompanies people’s longing for “eternal beauty” deep in their hearts and gives them confidence to keep moving forward. The company is Eternum Inc., headquartered at 1-21-17-7F Ebisu, Shibuya-ku, Tokyo. Its representative director is Takaaki Matsumoto, its business is cosmetics manufacturing and sales, and it was founded on July 3, 2023.